【摘要】 目的探讨西达本胺对外周T细胞淋巴瘤(PTCL)的疗效和安全性。方法 2015年4月—2017年9月福建省肿瘤医院淋巴瘤头颈部肿瘤内科收治PTCL患者25例,行西达本胺单药或联合治疗;治疗4个周期后,评价近期疗效,并观察远期生存情况及治疗期间药物不良反应发生情况。结果本组单药治疗客观有效率为62. 50%。1年和2年无进展生存率分别为56. 25%和43. 75%,中位无进展生存期为11个月。联合治疗客观有效率为55. 56%,1年和2年无进展生存率分别为77. 78%和66. 67%,中位无进展生存期为15个月。单药和联合治疗近期有效患者2年无进展生存率和中位无进展生存期均明显优于近期无效患者(P <0. 05)。本组共发生45例次不良反应,且均可耐受。结论西达本胺治疗PTCL有较好效果,且耐受性较好。更多还原

【Abstract】 Objective To investigate curative effect and safety of Chidamide in treatment of patients with peripheral T-cell lymphoma(PTCL). Methods A total of 25 patients with PTCL admitted during April 2015 and September2017 were treated with either Chidamide only or Chidamide combination therapy. After 4 cycles of treatment,short-term curative effect was evaluated,and conditions of long-term survival rate and incidence rate of adverse drug reactions during treatment were observed. Results The objective effective rate by only one drug was 62. 50%. The 1-year and 2-years progression-free survival rates were 56. 25% and 43. 75% respectively,and the median progression-free survival time was11 months. The objective effective rate of combination therapy was 55. 56%. The 1-year and 2-years progression-free survival rates were 77. 78% and 66. 67% respectively,and the median progression-free survival time was 15 months. The 2-years progression-free survival rate and the median progression-free survival rate of patients with effective short-term curative effect by only one drug and combination therapy were significantly better than those of patients with ineffective shortterm curative effect(P < 0. 05). Adverse reactions were found in 45 patients,and all patients could tolerate. Conclusion Chidamide is effective and can be tolerated in treatment of patients with peripheral T-cell lymphoma.更多还原